Advanced Search

 

Study ID Status Title Patient Level Data
114778 Completed Immunogenicity and safety study of GSK Biologicals’ Boostrix™ vaccine using a new syringe presentation in healthy adolescents aged 10–15 years Study Listed on ClinicalStudyDataRequest.com
114782 Active, Not Recruiting Drug Use Investigation for VOLIBRIS® (ambrisentan) (Pulmonary arterial hypertension)
114784 Completed A Phase I Trial of GSK1120212 and GSK1120212 in Combination with Gemcitabine in Japanese Subjects with Solid Tumors
114785 Terminated A pivotal, open-label trial assessing the safety and efficacy of the 0.5 mg dutasteride and 0.4 mg tamsulosin combination once daily for six months in patients with benign prostatic hyperplasia
114790 Completed Risk of cancer in patients exposed to gabapentin in the GPRD
114791 Completed Assessing the safety of inhaled zanamivir exposure in pregnant women
114793 Completed Blinded retrospective laboratory evaluations to assess the serologic response to Porcine circovirus type 1 (PCV-1) in infants following the administration of GlaxoSmithKline (GSK) Biologicals’ human rotavirus vaccine (444563)
114812 Completed A comparison of patients on AVAMYS ® versus NASONEX (A trade mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures
114819 Completed A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
114825 Completed Long term immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine 1437173A in healthy subjects
114837 Terminated A 16-week, Phase 2a, single-arm, multi-center, open-label study to evaluate the safety and efficacy of GSK1278863 after switching from recombinant human erythropoietin (rhEPO), in hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are chronically hyporesponsive to rhEPO Study Listed on ClinicalStudyDataRequest.com
114840 Terminated A randomized, single blind, placebo-controlled, single ascending dose/repeat dose cohort study to assess safety, tolerability, pharmacokinetics and immunogenicity of GSK1223249 in patients with relapsing forms of multiple sclerosis. Study Listed on ClinicalStudyDataRequest.com
114843 Completed Safety and immunogenicity of a booster dose of new formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine (GSK217744)
114849 Completed Dermal Safety Study of GSK2585823 (Clindamycin 1%-Benzoyl peroxide 3% gel) with Healthy Japanese Male and Female Subjects Study Listed on ClinicalStudyDataRequest.com
114855 Terminated A randomised, double-blind, placebo-controlled, parallel-group, multicentre study to determine the efficacy and safety of 2 doses of retigabine immediate release (900 mg/day and 600 mg/day) used as adjunctive therapy in adult Asian subjects with drug-resistant partial-onset seizures. Study Listed on ClinicalStudyDataRequest.com
114856 Completed A multidose study in subjects with type 2 diabetes mellitus to assess the pharmacokinetics and pharmacodynamics of albiglutide Study Listed on ClinicalStudyDataRequest.com
114858 Completed Immunogenicity and safety study of GSK Biologicals' meningococcal conjugate vaccine (GSK 134612) when co-administered with routine vaccines in healthy infants and toddlers
114866 Completed Incidence, Prevalence, and Symptom Burden associated with Advanced Renal Cell Carcinoma in commercially insured population (Pharmetrics)
114867 Completed Incidence, Prevalence, and Symptom Burden associated with Advanced Renal Cell Carcinoma in commercially insured population (IHCIS)
114870 Withdrawn A clinical and mechanistic proof of efficacy study with belimumab in chronic immune thrombocytopenia (ITP) patients.
114872 Completed An observational study to assess the burden of drug-resistant partial epilepsy in Italy
114873 Active, not recruiting A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults with Partial Onset Seizures (Extension of Study RTG114855)
114876 Completed An exploratory study to assess two doses of GSK2402968 in the Treatment of Ambulant boys with Duchenne Muscular Dystrophy
114877 Active, Not Recruiting Drug Use Investigation for REVOLADE (Chronic Idiopathic Thrombocytopenic Purpura)
114880 Completed Special Drug Use Investigation for Botox® (botulinum) Spasticity

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.